Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04882943
Other study ID # RC31/20/0378
Secondary ID 2020-A02774-35
Status Active, not recruiting
Phase
First received
Last updated
Start date May 6, 2021
Est. completion date June 1, 2026

Study information

Verified date May 2021
Source University Hospital, Toulouse
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Chronic cough (TC), defined by a duration exceeding 8 weeks, is a particularly frequent symptom with a prevalence observed at 9.6% 1. Chronic cough is the cause of a major handicap for patients with a impact on their quality of life 2. Although CT is common, management is often delicate and complex. In studies, asthma, gastroesophageal reflux disease, posterior flushing, rhino-sinusitis, or taking tussigenic medications are common causes of chronic coughs. However, chronic refractory or unexplained cough, which corresponds to cough for which no cause has been found or the treatments directed against the cause of the cough have not made it possible to resolve the cough, is a real problem in practice. nick3. There is currently no prospective data in France on the characteristics of chronic cough (etiologies, response to treatment) and the percentage of refractory cough. The aim of the study is to constitute a French prospective multicenter hospital cohort of chronic cough patients in order to identify, for the first time in France in a prospective and multicenter manner, the frequency of patients with refractory cough among chronic cough patients.


Description:

Visit V1: Visit as part of the treatment After obtaining no objection, the patient will complete cough questionnaires Visit V2: Visit as part of the treatment Visit carried out at 3 months with evaluation of the cough on the criteria of severity and quality of life. An evaluation of the response to treatments initiated at visit V1 will be carried out. Visit V3: Visit as part of the treatment Visit carried out at 6 months either by telephone if response to treatment at 3 months (at the discretion of the investigators) or in the investigative center if no response to treatment at 3 months. An evaluation of the cough on the criteria of severity and quality of life will be performed. Visit V4 to V8: Visit within the framework of research Phone call every 6 months made by a research technician. Patient severity and quality of life questionnaires will be issued in advance and completed at the time of telephone contact. The end of research visit corresponds to the V8 visit.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 576
Est. completion date June 1, 2026
Est. primary completion date June 1, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age =18 years old - Consultation motivated by cough lasting for more than 8 weeks (duration corresponding to the definition of chronic cough) - Patient covered by a National Health Insurance Exclusion Criteria: - Active smoker or recent smoking cessation (within the past 6 months) - Intake of medications causing cough (the patient can be included 4 weeks after treatment discontinuation if cough persists) - Pregnant or breast-feeding women - Upper or lower respiratory tract infection within the past 4 weeks - Active lung disease (such as interstitial lung disease, lung cancer, abnormal dilation of the bronchi). - History of chronic bronchitis. - Current treatment with an angiotensin converting enzyme (ACE) inhibitor - History of cancer within the past 5 years or active cancer (excluding cutaneous squamous-cell carcinoma). - Person not fluent in French - Adult not able to express his/her consent verbally - Patient refusal

Study Design


Related Conditions & MeSH terms


Intervention

Other:
questionnaires
Quality of life questionnaires

Locations

Country Name City State
France UHToulouse Toulouse

Sponsors (2)

Lead Sponsor Collaborator
University Hospital, Toulouse MSD France

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary French prospective multicenter hospital cohort of chronic cough patients (requency of patients with unexplained or refractory chronic cough (URCC) set up a French prospective multicenter hospital cohort of chronic cough patients in order to identify the frequency of patients with unexplained or refractory chronic cough (URCC) for the first time in France 24 months
See also
  Status Clinical Trial Phase
Completed NCT03282591 - Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Refractory Chronic Cough Phase 2
Completed NCT03407014 - Effect of Gefapixant (MK-7264/AF-219) on Cough Reflex Sensitivity in Healthy and Chronic Cough Participants (MK-7264-014) Phase 2
Completed NCT02476890 - Effect of Gefapixant (MK-7264/AF-219) on Cough Reflex Sensitivity in Healthy and Chronic Cough Participants (MK-7264-014) Phase 2
Recruiting NCT05599191 - A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough Phase 3
Recruiting NCT03662269 - Indomethacin for Refractory Chronic Cough Phase 3
Recruiting NCT05962151 - Refractory Chronic Cough Improvement Via NAL ER (RIVER) Phase 2
Recruiting NCT05110144 - Efficacy of Two Doses of Duloxetine and Amitriptyline in Subjects With Refractory Chronic Cough Phase 2
Enrolling by invitation NCT05733533 - A Study to Assess the Efficacy and Tolerance of HRS-2261 in Subjects With Refractory Chronic Cough Phase 2
Completed NCT02349425 - A Dose Escalation Study of Gefapixant (AF-219/MK-7264) in Refractory Chronic Cough (MK-7264-010) Phase 2
Recruiting NCT05600777 - A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough (CALM-2) Phase 3
Completed NCT05628740 - Placebo-controlled, Single and Multiple Dose Study in Healthy Volunteers and Refractory Chronic Cough Patients to Assess the Safety, Tolerability, and Pharmacokinetics of Two Formulations of NTX-1175 Phase 1
Not yet recruiting NCT06213363 - A Phase Ib/II Clinical Study in Patients With Refractory Chronic Cough Phase 1/Phase 2
Completed NCT02412020 - Treatment of Refractory Chronic Cough With PA101 Phase 2
Completed NCT04678206 - Evaluation of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough Phase 2
Completed NCT02612623 - An 8-Week Refractory Chronic Cough Study (MK-7264-021) Phase 2
Completed NCT02612610 - A 12-Week Study in Participants With Refractory Chronic Cough (MK-7264-012) Phase 2
Completed NCT02397460 - Effect of Gefapixant (AF-219/MK-7264) on Cough Reflex Sensitivity (MK-7264-015) Phase 2
Not yet recruiting NCT05265871 - ATP Level and Cough Sensitivity to ATP in Subjects With Refractory Chronic Cough